Imeglimin

DB12509InvestigationalSmall molecule

Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

Mechanism: Pharmacologically active on Gamma-secretase subunit PEN-2 and 5'-AMP-activated protein kinase
Curator reviewed
Formula / weight: C₆H₁₃N₅ · 155.205 g/mol (avg)
Code names: EMD-387008

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyGFICWFZTBXUVIG-SCSAIBSYSA-NSMILESC[C@@H]1NC(N)=NC(=N1)N(C)C

Targets

Transporters

What you can answer from here — as of September 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4TransportersSubstrate / inhibitor direction, not just membership

Listed above

34Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Imeglimin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.